메뉴 건너뛰기




Volumn 20, Issue 6, 2011, Pages 519-524

Estrogen receptor positive operable breast cancer: Does menopausal status impact on HER2 and progesterone receptor status?

Author keywords

Breast cancer; Estrogen receptor; HER2; Menopause; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR B; TUMOR MARKER;

EID: 82955163192     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.05.009     Document Type: Article
Times cited : (5)

References (21)
  • 1
    • 0031915998 scopus 로고    scopus 로고
    • Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    • Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
    • (1998) Mod Pathol , vol.11 , pp. 155-168
    • Allred, D.C.1    Harvey, J.M.2    Berardo, M.3    Clark, G.M.4
  • 2
    • 0032896905 scopus 로고    scopus 로고
    • Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    • Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
    • (1999) J Clin Oncol , vol.17 , pp. 1474-1481
    • Harvey, J.M.1    Clark, G.M.2    Osborne, C.K.3    Allred, D.C.4
  • 3
    • 44949121510 scopus 로고    scopus 로고
    • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    • Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
    • (2008) BMC Genomics , vol.9 , pp. 239
    • Loi, S.1    Haibe-Kains, B.2    Desmedt, C.3    Wirapati, P.4    Lallemand, F.5    Tutt, A.M.6
  • 4
    • 52049095087 scopus 로고    scopus 로고
    • A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
    • Ma X.J., Salunga R., Dahiya S., Wang W., Carney E., Durbecq V., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008, 14:2601-2608.
    • (2008) Clin Cancer Res , vol.14 , pp. 2601-2608
    • Ma, X.J.1    Salunga, R.2    Dahiya, S.3    Wang, W.4    Carney, E.5    Durbecq, V.6
  • 5
    • 33750985375 scopus 로고    scopus 로고
    • Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: clinical implications
    • Ciocca D.R., Gago F.E., Fanelli M.A., Calderwood S.K. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: clinical implications. J Steroid Biochem Mol Biol 2006, 102:32-40.
    • (2006) J Steroid Biochem Mol Biol , vol.102 , pp. 32-40
    • Ciocca, D.R.1    Gago, F.E.2    Fanelli, M.A.3    Calderwood, S.K.4
  • 6
    • 30944458620 scopus 로고    scopus 로고
    • Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy
    • Gago F.E., Fanelli M.A., Ciocca D.R. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 2006, 98:36-40.
    • (2006) J Steroid Biochem Mol Biol , vol.98 , pp. 36-40
    • Gago, F.E.1    Fanelli, M.A.2    Ciocca, D.R.3
  • 7
    • 33747819585 scopus 로고    scopus 로고
    • Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes
    • Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B., Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006, 37:1217-1226.
    • (2006) Hum Pathol , vol.37 , pp. 1217-1226
    • Kim, M.J.1    Ro, J.Y.2    Ahn, S.H.3    Kim, H.H.4    Kim, S.B.5    Gong, G.6
  • 8
    • 24744443547 scopus 로고    scopus 로고
    • Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    • Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97:1254-1261.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1254-1261
    • Arpino, G.1    Weiss, H.2    Lee, A.V.3    Schiff, R.4    De Placido, S.5    Osborne, C.K.6
  • 9
    • 72449138716 scopus 로고    scopus 로고
    • Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
    • Liu S., Chia S.K., Mehl E., Leung S., Rajput A., Cheang M.C., et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010, 119:53-61.
    • (2010) Breast Cancer Res Treat , vol.119 , pp. 53-61
    • Liu, S.1    Chia, S.K.2    Mehl, E.3    Leung, S.4    Rajput, A.5    Cheang, M.C.6
  • 10
    • 36048980544 scopus 로고    scopus 로고
    • Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype
    • Rakha E.A., El-Sayed M.E., Green A.R., Paish E.C., Powe D.G., Gee J., et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-4778.
    • (2007) J Clin Oncol , vol.25 , pp. 4772-4778
    • Rakha, E.A.1    El-Sayed, M.E.2    Green, A.R.3    Paish, E.C.4    Powe, D.G.5    Gee, J.6
  • 11
    • 33745195504 scopus 로고    scopus 로고
    • The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis
    • Punglia R.S., Kuntz K.M., Winer E.P., Weeks J.C., Burstein H.J. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 2006, 106:2576-2582.
    • (2006) Cancer , vol.106 , pp. 2576-2582
    • Punglia, R.S.1    Kuntz, K.M.2    Winer, E.P.3    Weeks, J.C.4    Burstein, H.J.5
  • 12
  • 13
    • 0037440261 scopus 로고    scopus 로고
    • Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
    • Konecny G., Pauletti G., Pegram M., Untch M., Dandekar S., Aguilar Z., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95:142-153.
    • (2003) J Natl Cancer Inst , vol.95 , pp. 142-153
    • Konecny, G.1    Pauletti, G.2    Pegram, M.3    Untch, M.4    Dandekar, S.5    Aguilar, Z.6
  • 14
    • 33645458120 scopus 로고    scopus 로고
    • Progesterone receptor and human epidermal growth factor receptor 2 status: an independent influence on the efficacy of endocrine therapy in breast cancer
    • Ponzone R., Maggiorotto F., Robba C., Fuso L., Sismondi P. Progesterone receptor and human epidermal growth factor receptor 2 status: an independent influence on the efficacy of endocrine therapy in breast cancer. J Clin Oncol 2006, 24:1481-1482.
    • (2006) J Clin Oncol , vol.24 , pp. 1481-1482
    • Ponzone, R.1    Maggiorotto, F.2    Robba, C.3    Fuso, L.4    Sismondi, P.5
  • 15
    • 0033811866 scopus 로고    scopus 로고
    • Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening
    • Rhodes A., Jasani B., Balaton A.J., Barnes D.M., Miller K.D. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000, 53:688-696.
    • (2000) J Clin Pathol , vol.53 , pp. 688-696
    • Rhodes, A.1    Jasani, B.2    Balaton, A.J.3    Barnes, D.M.4    Miller, K.D.5
  • 16
    • 34548536058 scopus 로고    scopus 로고
    • Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    • Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007, 25:3846-3852.
    • (2007) J Clin Oncol , vol.25 , pp. 3846-3852
    • Viale, G.1    Regan, M.M.2    Maiorano, E.3    Mastropasqua, M.G.4    Dell'Orto, P.5    Rasmussen, B.B.6
  • 17
    • 77955551055 scopus 로고    scopus 로고
    • American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    • Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796.
    • (2010) J Clin Oncol , vol.28 , pp. 3784-3796
    • Burstein, H.J.1    Prestrud, A.A.2    Seidenfeld, J.3    Anderson, H.4    Buchholz, T.A.5    Davidson, N.E.6
  • 18
    • 0026072872 scopus 로고
    • Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
    • Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
    • (1991) Histopathology , vol.19 , pp. 403-410
    • Elston, C.W.1    Ellis, I.O.2
  • 19
    • 33646198056 scopus 로고    scopus 로고
    • Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
    • Dowsett M., Houghton J., Iden C., Salter J., Farndon J., A'Hern R., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-826.
    • (2006) Ann Oncol , vol.17 , pp. 818-826
    • Dowsett, M.1    Houghton, J.2    Iden, C.3    Salter, J.4    Farndon, J.5    A'Hern, R.6
  • 20
    • 38749140648 scopus 로고    scopus 로고
    • HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
    • Santinelli A., Pisa E., Stramazzotti D., Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008, 122:999-1004.
    • (2008) Int J Cancer , vol.122 , pp. 999-1004
    • Santinelli, A.1    Pisa, E.2    Stramazzotti, D.3    Fabris, G.4
  • 21
    • 58049213826 scopus 로고    scopus 로고
    • Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
    • Van Calster B., Vanden B.I., Drijkoningen M., Pochet N., Cheng J., Van Huffel S., et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 2009, 113:181-187.
    • (2009) Breast Cancer Res Treat , vol.113 , pp. 181-187
    • Van Calster, B.1    Vanden, B.I.2    Drijkoningen, M.3    Pochet, N.4    Cheng, J.5    Van Huffel, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.